Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
COVID patients with weak immune systems should get priority care to avoid new variants emerging, experts say
03:10pm, Wednesday, 08'th Jun 2022 MarketWatch
Patients suffering from long-term symptoms of COVID-19 because they are immunocompromised should be prioritized for treatments because some variants have emerged in people who struggle to eliminate in
Gilead Sciences, Inc. (GILD) Management Presents at Jefferies Global Healthcare Conference - Transcript
01:06pm, Wednesday, 08'th Jun 2022
Gilead Sciences, Inc. (NASDAQ:GILD ) Jefferies Global Healthcare Conference June 8, 2022 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee
7 Oversold Stocks to Buy Right Now
07:00am, Wednesday, 08'th Jun 2022
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. The post 7 Oversold Stocks to Buy Right Now appeared first on Inv
Gilead Sciences: Buy The Dip
10:10pm, Tuesday, 07'th Jun 2022
Company beats earnings and sales estimates in the first quarter. Virology remains strong with oncology expected to grow significantly.
5 Dividend Stocks Gurus Are Building Positions In
05:49pm, Tuesday, 07'th Jun 2022
As investors continue to contend with market volatility, five high dividend yield stocks with a high number of guru buys as of the first-quarter 13F filing date are Verizon Communications Inc. ( VZ ,
Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?
03:31pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Sciences, Inc. (GILD) Management presents at Bernstein 38th Annual Strategic Decisions Conference - Transcript
11:54pm, Thursday, 02'nd Jun 2022
Gilead Sciences, Inc. (NASDAQ:GILD ) Bernstein 38th Annual Strategic Decisions Conference June 1, 2022 4:30 PM ET CorporateParticipants Andrew Dickinson - Chief Financial Officer ConferenceCall Partic
Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?
03:31pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Heart conditions and gender may increase the risk for long COVID, according to 23andMe
11:32am, Thursday, 02'nd Jun 2022 MarketWatch
The company asked 100,000 people to self-report data about long COVID; Shanghai exits lockdown; COVID-19 cases in the U.S. drop
ASCO Presentations Could Move Shares of Daiichi, AstraZeneca, Gilead and Roche
03:09pm, Tuesday, 31'st May 2022
Investors will want to keep an eye on developments at this week's meeting of the American Society of Clinical Oncology in Chicago, where four members of big pharma will share study results of their mo
7 Safe Dividend Stocks With High Yields to Buy Now
10:49am, Tuesday, 31'st May 2022
Investors are seeking dividend stocks. Here are seven safe dividend stocks that offer a high yield to maximize their total return.
Wide-Moat Stocks On Sale - The June 2022 Heat Map
07:20am, Tuesday, 31'st May 2022 Seeking Alpha
Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison.
Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah
07:10pm, Monday, 30'th May 2022 Zacks Investment Research
Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
02:33pm, Monday, 23'rd May 2022 Benzinga
Upgrades
According to Morgan Stanley, the prior rating for Motorola Solutions Inc (NYSE:MSI) was changed from Equal-Weight to Overweight. Motorola Solns earned $1.70 in the first quarter, compared to
The Zacks Analyst Blog Highlights JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical
10:22am, Monday, 23'rd May 2022 Zacks Investment Research
JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical have been included in this Analyst Blog.
